Overview

A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is: 1. To compare the efficacy of a single dose of Frovatriptan 2.5 mg with that of placebo in acute treatment of up to one migraine attract 2. To assess recurrence rate between two group 3. To assess the safety and tolerability

Phase:

Phase 3

Details

Lead Sponsor:

SK Chemicals Co., Ltd.
SK Chemicals Co.,Ltd.

Treatments:

Frovatriptan